Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference

BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that the Company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:30 p.m. EDT.

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem Oncology:

Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and RAF/MEK inhibition.

Our first FDA approved product is available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).

For more information, please visit www.verastem.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005057/en/

Verastem Oncology:

Investors:
John Doyle
Vice President, Investor Relations & Finance
+1 781-469-1546
[email protected]

Joseph Rayne
Argot Partners
+1 212 600 1902
[email protected]

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
[email protected]

Source: Verastem, Inc.

You May Also Be Interested In

• Verastem (VSTM) PT Lowered to $13 at Mizuho
• TNS: Rebuilding Trust in Voice Requires Protecting Both Caller Identity and the Numbers Behind It
• Embrace Pet Insurance Invests in the Long-Term Success of Veteran-Service Dog Teams